非霍奇金淋巴瘤

预约门诊

生存率

非霍奇金淋巴瘤的生存率因人而异。影响因素包括非霍奇金淋巴瘤的类型、患者整体健康状况、癌症分期及所接受的治疗。为了解非霍奇金淋巴瘤的生存率，专家研究了大量非霍奇金淋巴瘤患者，以了解确诊后 5 年生存人数比例。

1 期非霍奇金淋巴瘤患者存活至少 5 年的几率约为 88%。随着癌症扩散，生存率会逐渐降低。4 期非霍奇金淋巴瘤患者存活至少 5 年的几率约为 64%。

生存率因非霍奇金淋巴瘤类型而异。弥漫性大 B 细胞淋巴瘤是最常见的非霍奇金淋巴瘤类型。此类型具有侵袭性，因此生存率通常相对较低。1 期患者存活至少 5 年的几率为 80%。4 期弥漫性大 B 细胞淋巴瘤患者生存至少 5 年的几率约为 55%。

滤泡性淋巴瘤是另一种常见的非霍奇金淋巴瘤。此类型属于惰性淋巴瘤，生长速度缓慢。生存率通常较高。1 期滤泡性淋巴瘤患者存活至少 5 年的几率约为 97%。4 期滤泡性淋巴瘤患者存活至少 5 年的几率约为 83%。

请注意，生存率统计数据需要 5 年才能采集到。最新生存率数据包含 5 年前接受过非霍奇金淋巴瘤治疗的患者。这些患者可能未接受过最新疗法。在过去数十年间，非霍奇金淋巴瘤死亡率持续下降，生存率稳步提升。

申请预约
分期医生与科室
Nov. 07, 2025

Living with 非霍奇金淋巴瘤?

Connect with others like you for support and answers to your questions in the Blood Cancers & Disorders support group on Mayo Clinic Connect, a patient community.

Blood Cancers & Disorders Discussions

jak2mpnpositive
I have JAK2 ET and MPN: Anyone else have these symptoms?

114 Replies Mon, Aug 03, 2026

eddb
Anyone else find the side effects of Hydrea 500MG frightening?

212 Replies Sun, Aug 02, 2026

Lori, Volunteer Mentor
My Bone Marrow Transplant (BMT/SCT) story: Will you share yours?

912 Replies Fri, Jul 31, 2026

See more discussions
  1. B-cell lymphomas. National Comprehensive Cancer Network. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1480. Accessed Aug. 30, 2024.
  2. T-cell lymphomas. National Comprehensive Cancer Network. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1483. Accessed Aug. 30, 2024.
  3. Non-Hodgkin lymphoma (NHL). Leukemia & Lymphoma Society. https://www.lls.org/lymphoma/non-hodgkin-lymphoma. Accessed Sept. 16, 2024.
  4. DeVita VT Jr, et al., eds. Non-Hodgkin lymphoma. In: DeVita, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology. 12th ed. Wolters Kluwer; 2023. Accessed Aug. 28, 2024.
  5. Distress management. National Comprehensive Cancer Network. https://www.nccn.org/guidelines/guidelines-detail?category=3&id=1431. Accessed Aug. 29, 2024.
  6. Member institutions. Alliance for Clinical Trials in Oncology. https://www.allianceforclinicaltrialsinoncology.org/main/public/standard.xhtml?path=%2FPublic%2FInstitutions. Accessed Sept. 17, 2024.
  7. Member institution lists. NRG Oncology. https://www.nrgoncology.org/About-Us/Membership/Member-Institution-Lists. Accessed Sept. 17, 2024.
  8. Bock AM, et al. Bispecific antibodies for non-Hodgkin lymphoma treatment. Current Treatment Options in Oncology. 2022; doi:10.1007/s11864-021-00925-1.
  9. Tun AM, et al. Immunotherapy in Hodgkin and non-Hodgkin lymphoma: Innate, adaptive and targeted immunological strategies. Cancer Treatment Reviews. 2020; doi:10.1016/j.ctrv.2020.102042.
  10. Nowakowski GS, et al. Integrating precision medicine through evaluation of cell of origin treatment planning for diffuse large B-cell lymphoma. Blood Cancer Journal. 2019; doi:10.1038/s41408-019-0208-6.
  11. Laurent C, et al. Impact of expert pathologic review of lymphoma diagnosis: Study of patients from the French Lymphopath Network. Journal of Clinical Oncology. 2017; doi:10.1200/JCO.2016.71.2083.
  12. Paulson CL. Allscripts EPSi. Mayo Clinic. July 15, 2025.
  13. Cancer stat facts: Non-Hodgkin lymphoma. National Cancer Institute. https://seer.cancer.gov/statfacts/html/nhl.html. Accessed Oct. 1, 2025.
  14. Non-Hodgkin lymphoma treatment (PDQ) — Patient version. National Cancer Institute. https://www.cancer.gov/types/lymphoma/patient/adult-nhl-treatment-pdq. Accessed Oct. 1, 2025.
  15. Elsevier Point of Care. Clinical Overview: Non-Hodgkin lymphoma. https://www.clinicalkey.com. Accessed Oct. 1, 2025.
  16. Cancer stat facts: NHL — Diffuse large B-cell lymphoma (DLBCL). National Cancer Institute. https://seer.cancer.gov/statfacts/html/dlbcl.html. Accessed Oct. 1, 2025.
  17. Cancer stat facts: NHL — Follicular lymphoma. National Cancer Institute. https://seer.cancer.gov/statfacts/html/follicular.html. Accessed Oct. 1, 2025.

相关

相关医疗程序

Mayo Clinic 新闻

产品与服务

非霍奇金淋巴瘤